Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Deciphering Persistent Orofacial Pain - PIFP

25 de agosto de 2026 atualizado por: Kuan-Po Peng, Universitätsklinikum Hamburg-Eppendorf

Deciphering Persistent Orofacial Pain - Persistent Idiopathic Facial Pain

Persistent non-dental orofacial pain is common yet poorly characterised, and its pathophysiology remains largely unknown. Two clinically similar entities are distinguished: post-traumatic trigeminal neuropathic pain (PTNP), in which peripheral nerve damage is demonstrable, and persistent idiopathic facial pain (PIFP), in which peripheral findings are typically absent - pointing to an altered central processing of trigeminal nociceptive input. This monocentric study characterises the peripheral and central mechanisms of PIFP by comparing PIFP patients with age- and sex-matched healthy controls using a combination of non-invasive peripheral and central approaches.

The study comprises two work packages. The peripheral work package uses quantitative sensory testing (standardised DFNS protocol) to test the hypothesis that PIFP patients retain an intact peripheral nervous system. The central work package uses functional MRI with standardised trigemino-nociceptive stimulation to characterise brainstem network dynamics, testing the hypothesis that PIFP patients exhibit a central trigeminal processing disturbance at the brainstem level. In PIFP patients, the functional MRI is repeated before and after a local-anaesthetic nerve block in the pain area, additionally distinguishing patients whose pain is completely abolished by the block from those with persistent pain despite it. The overarching aim is to characterise the pathophysiological basis of PIFP and thereby advance the mechanistic understanding of persistent orofacial pain.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Descrição detalhada

Background and Rationale:

Persistent non-dental orofacial pain is common but poorly understood, and its underlying pathophysiology remains largely undefined. Two clinically similar entities can be distinguished. Painful post-traumatic trigeminal neuropathy (PTNP) is characterized by persistent pain accompanied by demonstrable somatosensory changes (negative signs such as hypoesthesia and hypoalgesia, and/or positive signs such as allodynia and hyperalgesia) in the painful area, typically following nerve injury. Persistent idiopathic facial pain (PIFP; formerly "atypical facial pain") is a constant, dull, poorly localized facial pain that does not follow the distribution of a single trigeminal branch, may cross the midline over time, and is not associated with a neuralgiform pain component; clinical and radiographic examinations are unremarkable. Because the two conditions are clinically nearly identical, patients frequently attribute the pain to dental causes, and unnecessary dental treatment or tooth extraction can aggravate and chronify the pain.

The absence of somatosensory deficits in PIFP suggests that altered central processing of trigeminal nociceptive input, rather than a purely peripheral mechanism, contributes to the pain. This is consistent with the concept of nociplastic pain, in which centrally altered sensory processing and pain modulation drive an augmented pain response. Prior high-resolution brainstem functional MRI (fMRI) work demonstrated that PIFP patients show stronger activation of the spinal trigeminal nucleus in response to standardized trigeminal nociceptive stimulation compared with healthy controls. However, fMRI alone cannot distinguish central sensitization (top-down) from a peripheral drive maintained by ongoing nociceptor input. This study therefore combines quantitative sensory testing (QST) with a trigemino-nociceptive fMRI paradigm that incorporates a peripheral nerve block, in order to characterize the peripheral and central contributions to PIFP.

Objectives and Hypotheses:

The overarching objective is to describe and characterize the pathophysiology of PIFP by comparing PIFP patients with age- and sex-matched healthy controls using non-invasive psychophysical and neuroimaging methods. The central hypothesis is that PIFP patients exhibit a disturbance of central trigeminal nociceptive processing at the brainstem level and in other critical trigeminal pain-processing regions, such as the thalamus and insula, that distinguishes them from healthy controls. A secondary hypothesis is that, within PIFP patients, a peripheral anesthetic nerve block will separate individuals whose pain is driven peripherally (pain abolished during the block) from those whose pain is maintained centrally/nociplastically (pain persists despite cutaneous numbness), and that these subgroups differ in their central nociceptive processing.

Study Procedure:

Participants are assigned to groups by clinical diagnosis; there is no randomization or blinding. Two components are applied to all participants: standardized psychophysical/sensory characterization and task-based fMRI with standardized electrical trigemino-nociceptive stimulation. Patients are recruited through the headache/facial pain outpatient clinic; healthy volunteers are recruited via public postings and local internet platforms. The study plans to enroll 30 patients with PIFP together with 30 age- and sex-matched healthy controls for comparison. Patients are recruited through the headache/facial pain outpatient clinic; healthy volunteers are recruited via public postings and local internet platforms.

Clinical and Psychophysical Characterization:

All participants complete standardized questionnaires for deep phenotyping, including the Patient Health Questionnaire (PHQ-9), central sensitization inventory (CSI), brief pain inventory (BPI), short form-36 health survey (SF-36), and custom instruments covering general health, medication and stimulant use, dental history, and oral hygiene, as well as detailed pain history, pain character and intensity, prior treatments, and potential triggering events. Patients undergo a standardized extraoral and intraoral dental examination, including palpation of the trigeminal exit points and masticatory apparatus and standardized oral health indices. Quantitative sensory testing is performed in all participants over the trigeminal dermatomes bilaterally, following the standardized protocol of the German Research Network on Neuropathic Pain (DFNS). Thermal thresholds are assessed with a thermal sensory analyzer, and mechanical stimuli with von Frey filaments and Pinprick stimulators.

Functional MRI Paradigm:

Task-based fMRI is acquired on a 3T scanner using a brainstem-optimized high-resolution protocol. Standardized nociceptive stimulation is delivered via an MR-compatible constant-current stimulator coupled to MR-safe electrodes positioned over the second (V2) and third (V3) branches of the trigeminal nerve bilaterally. After determination of individual electrical pain thresholds, stimulation intensity is set at 3 times the pain threshold and capped at 10 mA to remain tolerable and safe. Four stimulation sites, bilateral V2 and V3, are presented in randomized order with repeated trials across sessions, and participants rate perceived pain intensity after the first trial and for every 10 trials on each stimulation site. This paradigm probes the functional representation of trigeminal nociceptive input in the spinal trigeminal nucleus, thalamus, insula, and related brainstem structures.

PIFP patients who consent are scanned twice with this paradigm: before and after a local-anesthetic nerve block administered in the painful area by a dentist. This design distinguishes patients in whom the pain is abolished while the area is anesthetized (suggesting a predominantly peripheral, nociceptor-driven mechanism) from those in whom cutaneous numbness is achieved but the pain persists (suggesting a central, nociplastic mechanism).

Outcome Measures:

The primary outcome is the difference in the fMRI response to standardized trigemino-nociceptive stimulation within trigeminal pain-processing regions - including the spinal trigeminal nucleus, thalamus, and insula - in the following comparisons: (i) PIFP patients versus healthy controls; and (ii) within PIFP patients, the difference in activation before versus after the local-anesthetic nerve block, and between patients whose pain is completely abolished by the block versus those with persistent pain despite the block. Secondary outcome includes: (1) comparison of deep phenotyping and QST parameters between PIFP patients and healthy controls

Statistical Analysis:

The primary analysis requires 20 complete datasets per cohort. Based on previous studies with this population and sequence, approximately 25% of enrolled participants are expected to yield unusable data (dropout, excessive head motion, or incidental findings). Neuroimaging data are analyzed using a general linear model with statistical parametric mapping, contrasting the painful side versus the control side, and comparing groups and pre/post nerve-block conditions. For the fMRI data, a family-wise error-corrected threshold of PFWE < 0.05 will be applied at the whole-brain level, except for a priori regions of interest - the spinal trigeminal nucleus, thalamus, and insula - for which small-volume-corrected PFWE < 0.05 will be used. Psychophysical and QST parameters are compared between groups using parametric or non-parametric tests as appropriate after testing distributional assumptions, with a two-sided significance level of p < 0.05. Analyses are performed after completion of data collection; no interim analyses are planned.

Tipo de estudo

Observacional

Inscrição (Estimado)

60

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Arne May, MD, PhD
  • Número de telefone: +49 40 74105 9189
  • E-mail: a.may@uke.de

Estude backup de contato

  • Nome: Kuan-Po Peng, MD
  • Número de telefone: +49 40 74102 7305
  • E-mail: k.peng@uke.de

Locais de estudo

      • Hamburg, Alemanha, 20246
        • University Medical Center Hamburg-Eppendorf
        • Contato:
          • Kuan-Po Peng, MD
          • Número de telefone: +49 40 74102 7305
          • E-mail: k.peng@uke.de

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Método de amostragem

Amostra Não Probabilística

População do estudo

Patients with PIFP will be recruited from the headache/facial pain outpatient clinic of the University Medical Center Hamburg-Eppendorf

Descrição

Inclusion Criteria:

  • Healthy controls: written informed consent.
  • PIFP cohort: written informed consent, and a diagnosis of PIFP according to the ICHD-3 and ICOP diagnostic criteria.

Exclusion Criteria:

  • Contraindication to MR scanning
  • Anxiety disorders, including claustrophobia
  • Other somatic diseases, including other pain disorders
  • Other primary headache disorders and medication-overuse headache
  • Skin lesion , infection, or scarring at the stimulation sites preventing safe electrode placement
  • Healthy volunteers: any history of persistent pain or primary headache, including in first-degree relatives
  • History of psychiatric disease and/or addiction
  • Pregnancy or lactation
  • Any regular medication; in PIFP patients, occasional acute analgesic use (NSAID, fewer than 8 days per month) is permitted
  • Use of acute analgesic within 24 hours before the experiment

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Patients with persistent idiopathic facial pain (PIFP)
Patients with persistent idiopathic facial pain
Age- and sex-matched healthy controls (HC)

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Difference in brain functional neuroimaging response to standardized trigemino-nociceptive stimulation between PIFP patients HC
Prazo: Baseline (MRI session before local anesthesia)
BOLD signal change (contrast estimates, arbitrary units) during standardized trigemino-nociceptive stimulation versus baseline, compared between PIFP patients and HC in a priori defined regions of interest and at whole-brain level.
Baseline (MRI session before local anesthesia)
Difference in brain activation before versus after the local-anesthetic nerve block, and between complete responders and non-responders
Prazo: Pre-block MRI at baseline and post-block MRI, both on the same day 1
BOLD signal change (contrast estimates, arbitrary units) during standardized trigemino-nociceptive stimulation, compared within participants before versus after the local-anesthetic nerve block, and between participants whose pain is completely abolished by the block and those with persistent pain despite the block
Pre-block MRI at baseline and post-block MRI, both on the same day 1

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Comparison of deep phenotyping and quantitative sensory testing (QST) parameters between the study cohorts (PIFP versus HC).
Prazo: Baseline (single assessment before local anesthesia)
Standardized DFNS quantitative sensory testing parameters (thermal and mechanical detection and pain thresholds), compared between PIFP patients and HC.
Baseline (single assessment before local anesthesia)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Arne May, MD, PhD, Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de setembro de 2026

Conclusão Primária (Estimado)

30 de junho de 2029

Conclusão do estudo (Estimado)

31 de outubro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

18 de agosto de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de agosto de 2026

Primeira postagem (Real)

27 de agosto de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

27 de agosto de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

25 de agosto de 2026

Última verificação

1 de agosto de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2024-101254-BO-ff-PIFP

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data (IPD) will not be shared with other researchers. Data are collected and analyzed in pseudonymized form, and results will be reported and published only in aggregated, anonymized form that does not permit identification of individual participants. The pseudonymization key is held exclusively by the study leadership and is deleted as soon as the research purpose allows. Consistent with the informed consent obtained from participants and the approved data protection concept, no de-identified individual-level datasets will be made available externally.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .